

N EANE HE I AND B ANCE E

! "\$%&'(&)*+,-&. /0-&12-&324)-&)332-&. #*5\$66*#
. 7#87\$&9%, : \$#6, ; <&=> / ** +&*5&27#6,%?
. # \$6\$%; \$8&" ; & ; / \$&2@=A2&
BCBD&=>, \$%; ,5,>&=<EF*6,7EG&)#* E&O"; "&; *&. *+,><



! "#\$%#%&' #()#"\$%#*+%,%&"-".(&/#"#\$%#* -+"0.* -&"#1.22#3%#-32%#" (4

! ! "#\$%&' "())&#*+%&\$,-(&./+%0,*&+.(%"-,*"1(*+(#2' #*,. \$"(2#"(& (\$"%*&/&'1(%"3&#*"%"1(. 2%#"(. "#*)""*&#*(45678#9:

! 6"\$,-(*)"O"#(#2%+2. 1&. 3(#2' #*,. \$"(2#"(&. (5678#(' ,#"1(+.(; 2,-&*, *&<"(1, *, :

! =&#*(, *(-", #*(/(&<"(+/(*)"(8O"%&\$, . (8##+\$&, *&+.(+/(72%#" (8. "#*)"#&+--+3>(488789(%"\$+OO". 1"1(#*%, "*"3&"#(*+(O&. &O&?"(1%23(1&<"%#&+. :(

! @1". *&/>(*)"(", ##+\$&, *&+.#(' ""A"" . (*)"(&OB-"O". "*"1(8878(#*%, "*"3&"#(,. 1(B"%\$"&<"1("//"\$*&<". "##(+/(*)" (#*%, "*"3&"#:

! 5+. #&1"%(. +<"-(/&. 1&. 3#(, . 1(\$+. \$-2#&+. #(/%+O(O"%3"1(1, *, :



!"#\$%&' () * +, -) #". -/01&

! 8. . , (C+%#*"%(EFD(67D(G)!

! =+%""** , (8. . (H+#*&\$D(! 7Q(8G67D(5678D(GE I 7GJH5

! K">2(K) , . 3D(EF

! =&. 3#+. 3(K) , . 3D(G)!

! =&. 1, (F*+. "D(! 7Q(5678

! F*21>(#B+. #+% "1(' >(*) ""(7, *&+. , -(5+2. \$&-(+/(F*, ""(H+, %1#(+/(
72%#&. 3L(5". *""%/+%(6"32-, *+%>(MN\$"--". \$"(4G%+0"\$*(P6QRSSRRT9



567! ,#-&' #893,"-&0%#: ,%#

! VSDRRR(5678#(, . 1(67(, . "#*) "#&, (%"#&1" . *#(&. (\$-&. &\$, -(#"**&. 3#(48878D(QRQQ9:

! G%, \$*&\$"(&. (A&1"(% , . 3"(+/() " , -*)\$, %"("#**&. 3#D(&. \$-21&. 3(+B"% , *&. 3(%++O#D(+//&\$"#(/+%1" . *&#*#D(B+1&, *&#*#D(+B)* , -O+--+3&#*#D(B-, #*&\$(#2%3"+. #D(, . 1(B, &. (O, . , 3"O" . *(#B"\$&, -&#*#:

! W%&. X+//("*(, -(4QRQQ9L(

Nurses overall: 11.4% for SU problems; and **6.6% SUD**

APRNs: 15.2% SU problem and **4.0% SUD**

OR/PACU/Outpatient surgery/Anesthesia: 7.9% SU problems;
7.1% SUD



567! ,#-&' #893,"-&0%#: ,%#

! 5678#L(6&#X(/+%FU! #L(

Moderate risk: 23.56% for Alcohol; 10.27% Tobacco; and 6.28% for Cannabis (Foli et al., 2023).



59++%&"#8"9' ;

! Y), *(, %"(*)"(<2-. "%, ' &-&*&"#(+/(5678#(*+(&. &*&, *&+. (+/(FUD(
%"\$2%%". \$"D(, . 1(+<"%, --(B"%\$"B*&+. #(%"-, *"1(*+(FUZ

! 8%("\$2%%". *(8878(%"\$+OO". 1"1(#*%, *"3&"#(*+(, <+&1(
1&<"%#&+. (' "&. 3(&OB-"O". *"1 &. (*)"(+%3, . &?, *&+. D(, . 1()+A(
1+"#(&OB-"O". *, *&+. (\$+OB, %"(A&*)(B"%\$"&<"1(
"/"\$*&<". "##Z(

! @. (O"%3&. 3(*)"(*A+(*>B"#(+/(1, *, D(A), *(. "A(&. #&3)*#(
#2%+2. 1&. 3(5678(FU \$, . (' "(3, &. "1Z(



<%"\$ (' ,

! 8878(6"#", %\$(F"%&\$"#(2#"1(*+(1"B-+>(+ . -&. "(
#2%<">(<&, ([2, -*%&\$#

! \]R(&. \$" . *&<"(+//"%1

! ^DRRR(8878(O"O' "%#("#" . *(#2%<">(&. (C"" %2, %>(
QRQS(

! Q_R(%"#B+. #"#` (Sa]JQQ](#2%<">#(A&*)(T]b(+/(&*""O#(
\$+OB-""1





> *%&?@&' %' #."%= ,

! Y), *(, 11#(*+(*))("<2-. "%, ' &-&*>(+/ (2#&. 3(#2' #*, . \$"#Z

! Y), *(A, #(), BB". &. 3(, *(*)"(*&O"(+/ (/&#*(#2' #*, . \$"(2#"Z

! Y), *(%&33%"1(%"\$2%" . \$"(+/FUZ

! 811&*&+. , -(\$+OO". *#(%"-, *"1(*+(#2' #*, . \$"(+%(, -\$+)+-(2#"(+%(&OB, &%O". *:



!"#\$%&'&(')&)*#+, -. //, %- , *#(%0#+, -)1, /2#

Question 1: What is happening in one's current work environment that adds to their vulnerability to substances?

Events and context aggravate SO in CPTs. These factors are magnified with unique environment and role. 1B. System issues and workplace environment contribute to SO and diversion.

The pandemic creates more vulnerabilities to feel stress and use substances.

H7\$6;, *%&I &JKL&#\$6F *%6\$6&"%" +<M\$8N

=<6;\$E&,667\$6&"%8&O *#PF+">\$&\$%: ,#*%E\$%;&>*%87>, : \$&,*&

=9&"%8&8, : \$#6,*%



! " # \$ % & ' () * + , - . / : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [\] ^ _ ` { | } ~ ¡ ¢ £ ¤ ¥ ¦ § ¨ © ª « ¬ ® ¯ ° ± ² ³ ´ µ ¶ · ¸ ¹ º » ¼ ½ ¾ ¿

Question 2: What was happening at the time when one first began using substances?²

Initiation of SU: Coping with personal and professional stressors 2A. Initial relief, then dependence

Question 3: What was happening that triggered a recurrence in SU?³

Tried to stop, but...: Failure to remain abstinent 3A. Going it alone



H7\$6;,*%&BG&JKQ&#\$6F*%6\$6&"%"<M\$8N

R%,,:,";,*%&*5&=9G&@*F,%?&O,;/&F\$#6*%"&"%8&F#*5\$66,*%"&

6;#\$66*#6



H7\$6;,*%&KG&JBI &#\$6F*%6\$6&"%"<M\$8N
S#,\$8&,*&6;*F-&T7;U(&)" ,+7#\$&,*&#\$E" ,%&"T6;,\$\$%;



!"#\$%&'&(')&)*#+, -. //, %- , *#(%0#+, -)1, /2#

Question: Additional comments related to substance or alcohol use or environment

Barriers for seeking help

4A. Regulator

Vulnerabilities of being

likely

4C. Outcomes of SU

Red flags and identifying those with SUDs

4D. Over and over symptoms

Drugs of choice: Alcohol, diversion, anesthesia safe substances

Cannabis



H7\$6;,*%&DG&JDI &#\$6F*%6\$6&"%"<M\$8N
. \$%" +;,\$6&5*#&6\$\$P,%?&/ \$+F





3343#5)%6&0, / ('&)%6#7)/#8/. 9#8&1, /6&)%#: /, 1, %'&)%6

AANA Considerations for Drug Diversion Prevention Strategies: Organizational Implementation and Effectiveness

Variable	n	Implemented ¹ M (SD)	Effective ² M (SD)	p Value
1. Institute random drug testing	198	1.32 (1.19)	3.15 (1.82)	<0.001
2. Install automated drug dispensers	198	2.76 (1.51)	3.32 (1.62)	0.001
3. Return all unused medication to a centralized location	197	2.65 (1.44)	3.42 (1.69)	<0.001
4. Secure return bins	198	2.35 (1.54)	3.45 (1.74)	<0.001
5. Audit anesthesia records	198	2.43 (1.35)	3.70 (1.53)	<0.001
6. Witness disposal of excess waste from medications	197	2.86 (1.48)	3.32 (1.61)	0.007
7. Collaborate with other departments to create reconciliation systems	195	2.67 (1.62)	3.51 (1.50)	<0.001
8. Investigate medication discrepancies	198	3.20 (1.34)	3.82 (1.29)	<0.001
9. Withdraw substances for only one patient at a time and administer in a controlled setting	197	2.99 (1.05)	3.40 (1.00)	0.012
10. Implement policies and procedures for investigations and management of confirmed diversions	197	2.52 (1.72)	3.68 (1.34)	<0.001
11. Create safe environment for prompt reporting to discourage drug diversions	197	2.52 (1.72)	3.68 (1.34)	<0.001



1\$?7+";*#<&"%8&V#?"%,M";,*%"&REF+,>" ;,*%6

! !"#\$\$%&' (%)*(&+, -. 1 (-)



! F"-/J%"B+%*"1(1, *, (#2%%+2. 1&. 3(, (#". #&*&<"(*+B&\$:

! =+A(%"#B+. #"(%, *"(-&X"->(12"(*+(1, *, (\$+--"\$*&+. (12%&. 3(
*)"(5de@ JSa(B, . 1"O&\$:

! 5678#(A"%("&OB, \$*"1(' >(B, *&". *(. ""1#(12%&. 3(
B, . 1"O&\$(A&*)(' +*)(&. \$%" , #*1(, . 1(1"\$%" , #*1(, \$*&<&*"#:(



!



|



! " #\$\$%&' ()! ** +&% ,%+ ()+-). /\$*#) ! (#*,0#*%+1+234)5! /2/*,)676684)90' ,),+): (+;)' <+/,)
<#&+" %(2)')=>. ! 4)/*?' <+/,&\$(' *?'<#&+" #@'
&\$('?ABCB,#D,EF +\$#G67,0' (G676G6=H77G67*,/I # (,G67\$#2% ,#\$#I JK
\$' &,%&#G67*#,,%(2*G67+-G67#L#\$3G67,3K#4
M#11J)N4)F 4J)F &N+ (+/20J)04)P4J)Q11% + (J)04)R4J)S)T%U0/20J)Q4)=4)5VWWW84)=+ (,\$+11#I)I \$/2)
" %/*#)<3)&#\$,%%#I)\$#2% ,#\$#I)(/\$*#)' (#*,0#,% ,*4)!! " ! #\$\$%&' ()*# , -568J)VXXYVH74
T+1%)Z4)04J)T+\$,#\$J)! 4J)M+* ,%&J)[4]! 4J)\O' (2J)\4J)\O' (2J)[4J)S)R,+ (#J)[4]5] (P\$**84)P\$#I %&,+ \$*)+ -)
/<, ' (&#)/*#)\$%*:)%(/\$*#)' (#*,0#,% ,*4)\$%&' ()*%.#! //0120%(3#" &'30(44)
T+1%)Z4)04J)T+\$,#\$J)! 4J)M+* ,%&J)[4]! 4J)\O' (2J)\4J)\O' (2J)[4J)S)R,+ (#J)[4]5676684). /\$*#)
' (#*,0#,% ,*B)=/\$\$#(,)K#&#K,%+ (*)' (I)K\$' &,%&#*)\$#1' ,#I),+)*/<*, ' (&#)/*#4)
\$%&' ()*%.#" &'30(4#564&*)20% (#785H8J)6X@XH4)O, K*B??I +%+\$2?V74V7V^?R6V___@
`6_^56687777`@H)
a\$%(:+--J)! 4)F 4J)R#1<3J)b4)[4J)c' (J)Z4J)M' &: J)c4J)R,##1#J)04J)QI ; %(J)c4)R4J)d++ (J)04)F 4J)S)R,+ \$J)=4)
[4]5676684)a0#)K\$#L' 1# (&#)+-)*/<*, ' (&#)/*#)' (I)*/<*, ' (&#)/*#)K\$+<1#" *)%(
\$#2% ,#\$#I)(/\$*#*B)Q* ,%' ' ,#*)-\$+ "),0#). /\$*#)9+\$: 1%#)' (I)9#11(#**R,/I 34)\$%&' ()*#
%.#" &'30(4#564&*)20% (#785H8J)X_@H^4)
9\$%20,J)Q4)[4J)F &e/\$(#**J)a4J)F + (#30" " J)[4N4J)R&O/" ' &O#J)04)Q4J)\; #1%(2J)! 4J)S)
R,/11# (<' \$2#\$J). 4)Q4). 4)567V684)fK%+%)' </*#)' " + (2)(/\$*#)' (#*,0#,% ,*)' (I)
' (#*,0#*%+1+2% ,*4)!! " ! #\$\$%&' ()*#9: 568J)V67YV6`4



Sample Demographics (n = 225)

Variable	n	%
Gender (n = 225)		
Male	86	38.22%
Female	138	61.33%
Other	0	0.0%
Decline to answer/missing	1	0.44%
Residence (n = 225)		
Urban	200	99.5%
Rural	1	0.5%
Race/Ethnicity (n = 218)		
Caucasian/White	100	45.87%
African American/Black	9	4.0%
Native American	0	0.0%
Hispanic American	5	2.22%
Asian American/Pacific Islander	10	4.4%
Bi-racial/multi-racial	2	0.89%
Other	8	3.67%
Hispanic/Latino (n = 225)		
Yes	13	5.78%
No/decline to answer	212	94.22%

Marital Status (n = 225)

Married	163	72.44%
Living as if married	14	6.22%
Widowed/divorced/separated	24	10.67%
Never married	23	10.22%
No response	1	0.44%

Highest Education (n = 221)

Master's degree or MSN	171	77.38%
DN	38	17.2%
PhD or DNS	4	1.81%
Terminal degree outside of nursing	3	1.36%
Certificate/diploma nurse anesthesia	5	2.26%
Other	2	0.90%

Personal Income (n = 225)

<\$25,000	4	1.78%
\$25,000-\$49,999	2	0.89%
\$50,000-\$74,999	5	2.22%
\$75,000-\$99,999	5	2.22%
Decline to answer	119	52.9%

Years as Practicing CRNA (n = 217)

≤10	85	41.06%
11-20	65	31.40%
21-30	36	17.39%
31-40	19	9.18%
41-50	2	0.97%

! " # \$ % & ' () * + , - . / : ; , % - , * # (% 0 # + , -) 1 , / 2 #

Themes and Subthemes: SU Initiation, Recurrence, and Recovery

Theme	Subtheme
<p>Question 1: What is happening in one's current work environment and/or personal life that adds to the vulnerability of using substances?</p> <p>Events and context aggravate vulnerabilities are magnified with unique environment and</p> <p>The participant creates more vulnerabilities to feel stress substances.</p>	<p>1A. Personal risk factors and symptoms of SU</p>
<p>Question 2: What was happening at the time when one first began using substances?</p> <p>Initiation of SU. Coping with persons and pro</p>	<p>2A. Coping with persons and pro</p>
<p>Question 3: What was happening that triggered a recurrence in SU?</p> <p>Tried to stop</p>	<p>3A. Going it alone</p>
<p>Question 4: Additional comments related to substance or alcohol use or impairment.</p> <p>Penalties for seeking help</p> <p>Vulnerabilities of being a CRNA</p>	<p>4A. Regulatory organization and near punishments</p> <p>4B. Access to drugs, stress, work conditions make it likely</p> <p>4C. Outcomes of SU</p>
<p>Red flags and identifying</p> <p>Drugs of choice and cannabis</p>	